<?xml version="1.0" ?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:seo="http://purl.org/seo/elements/1.0/" version="2.0">
	<channel>
		<title>Adia Med Inc. News Releases</title>
		<link>https://feeds.newsfilecorp.com/company/10520</link>
		<description>Latest news from Adia Med Inc., as distributed by TMX Newsfile.</description>
		<language>en</language>
		<copyright>CopyRight (c) 2026, Newsfile Corp. All Rights Reserved.</copyright>
		<managingEditor>office@newsfilecorp.com (Newsfile Corp.)</managingEditor>
		<webMaster>office@newsfilecorp.com (Newsfile Corp.)</webMaster>
		<lastBuildDate>Tue, 17 Nov 2026 12:30:07 -0500</lastBuildDate>
		<image>
			<url>https://images.newsfilecorp.com/logos/10520.jpg</url>
			<title>Adia Med Inc. News Releases</title>
			<link>https://feeds.newsfilecorp.com/company/10520</link>
		</image>
		<atom:link rel="self" type="application/rss+xml" href="https://feeds.newsfilecorp.com/company/10520"/>
		<item xml:lang="en">
			<title>ADIA Med Nearly Doubles Nine-Month Revenue to Surpass $1 Million</title>
			<link>https://www.newsfilecorp.com/release/324337/ADIA-Med-Nearly-Doubles-NineMonth-Revenue-to-Surpass-1-Million</link>
			<description>Third-quarter revenue up 37% as company strengthens balance sheet with $1.5 million Adia Labs transaction Winter Park, Florida--(Newsfile Corp. - November 17, 2026) - ADIA Med, Inc. (OTCQB: ADIA) today announced that revenue for the nine months ended September 30, 2026 rose approximately 95% to $1,019,245, up from $521,958 in the same period last year, crossing the $1 million mark."Medical procedure revenue more than doubled year-over-year in the first nine months, and the Adia Labs transaction...&lt;img src="https://api.newsfilecorp.com/newsinfo/324337/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 17 Nov 2026 08:00:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/324337</guid>
			<atom:subtitle>Third-quarter revenue up 37% as company strengthens balance sheet with $1.5 million Adia Labs transaction</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>Adia Med CEO Larry Powalisz Issues Open Letter on Leadership Journey, Research Mission, and Progress Since 2024</title>
			<link>https://www.newsfilecorp.com/release/322882/Adia-Med-CEO-Larry-Powalisz-Issues-Open-Letter-on-Leadership-Journey-Research-Mission-and-Progress-Since-2024</link>
			<description>Winter Park, Florida--(Newsfile Corp. - November 9, 2026) - Adia Med Inc. (OTCQB: ADIA) today released the following open letter from Chief Executive Officer Larry Powalisz outlining the company's progress since the January 2024 leadership transition, its regenerative medicine research mission, and efforts to generate evidence that could support broader access to investigational therapies.An Open Letter from Larry Powalisz, CEO of Adia Med Inc.November 5, 2026Winter Park, FloridaTo Our...&lt;img src="https://api.newsfilecorp.com/newsinfo/322882/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Mon, 09 Nov 2026 08:00:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/322882</guid>
		</item>
		<item xml:lang="en">
			<title>Adia Med Reports No Serious Adverse Events in First Cohort of Pediatric Autism Study; Enrollment Continues</title>
			<link>https://www.newsfilecorp.com/release/320413/Adia-Med-Reports-No-Serious-Adverse-Events-in-First-Cohort-of-Pediatric-Autism-Study-Enrollment-Continues</link>
			<description>No serious adverse events reported in either study arm; enrollment and participant follow-up continue Winter Park, Florida--(Newsfile Corp. - October 26, 2026) - Adia Med Inc. (OTCQB: ADIA) today reported interim safety observations from the first cohort of its randomized Phase 1/2 investigational study in children with autism spectrum disorder (ASD). Investigators reported no serious adverse events in either study arm and no events requiring reporting to the Institutional Review Board (IRB)....&lt;img src="https://api.newsfilecorp.com/newsinfo/320413/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Mon, 26 Oct 2026 08:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/320413</guid>
			<atom:subtitle>No serious adverse events reported in either study arm; enrollment and participant follow-up continue</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz for $350,000 in Cash</title>
			<link>https://www.newsfilecorp.com/release/319712/Adia-Med-Sells-7-Economic-Interest-in-Adia-Labs-to-CEO-Larry-Powalisz-for-350000-in-Cash</link>
			<description>Winter Park, Florida--(Newsfile Corp. - October 20, 2026) - Adia Med, Inc. (OTCQB: ADIA) today announced that its Chief Executive Officer, Larry Powalisz, purchased a 7% economic interest in Adia Labs LLC for $350,000 in cash. Under the completed Membership Interest Purchase Agreement, Powalisz purchased seven membership units at $50,000 per unit. The Company has filed a Current Report on Form 8-K relating to the transaction.Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz...&lt;img src="https://api.newsfilecorp.com/newsinfo/319712/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 20 Oct 2026 08:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/319712</guid>
		</item>
		<item xml:lang="en">
			<title>Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position</title>
			<link>https://www.newsfilecorp.com/release/318700/Adia-Med-Fully-Repays-RelatedParty-Credit-Facility-Strengthening-Its-Financial-Position</link>
			<description>Full repayment eliminates the Company's unsecured revolving credit facility and simplifies its remaining obligations Winter Park, Florida--(Newsfile Corp. - October 13, 2026) - Adia Med, Inc. (OTCQB: ADIA) (the "Company") today announced the full repayment and discharge of its unsecured revolving line of credit with Larry Powalisz, the Company's Chief Executive Officer.Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial PositionTo view an enhanced version of this...&lt;img src="https://api.newsfilecorp.com/newsinfo/318700/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 13 Oct 2026 09:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/318700</guid>
			<atom:subtitle>Full repayment eliminates the Company's unsecured revolving credit facility and simplifies its remaining obligations</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>Adia Med Partners with Live Oak Health (dba QCM Biologics) as Distributor and Sells 30% Stake in Adia Labs for $1.5 Million</title>
			<link>https://www.newsfilecorp.com/release/317634/Adia-Med-Partners-with-Live-Oak-Health-dba-QCM-Biologics-as-Distributor-and-Sells-30-Stake-in-Adia-Labs-for-1.5-Million</link>
			<description>Winter Park, Florida--(Newsfile Corp. - October 6, 2026) -  Adia Med Inc. (OTCQB: ADIA) today announced that it has sold a 30% interest in Adia Labs LLC to Live Oak Health, a stem cell distributor doing business as QCM Biologics, for $1.5 million, and that the sale is paired with a distribution partnership. The Company has filed a Form 8-K related to the transaction.Link to Form 8-K here: Inline Viewer: ADIA MED, INC. 8-K 2026-09-30The transaction includes $1.0 million in cash and a $500,000...&lt;img src="https://api.newsfilecorp.com/newsinfo/317634/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 06 Oct 2026 09:20:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/317634</guid>
		</item>
		<item xml:lang="en">
			<title>Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line</title>
			<link>https://www.newsfilecorp.com/release/316434/Adia-Med-Inc.-Announces-Adia-Labs-Expansion-of-Regenerative-Product-Line</link>
			<description>New research-use products - Adia30M, AdiaClear, and AdiaEXO - give physicians more options in cell count, format, and concentration for investigational studies. Winter Park, Florida--(Newsfile Corp. - September 29, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that its laboratory subsidiary, Adia Labs LLC, has expanded its product portfolio with three new...&lt;img src="https://api.newsfilecorp.com/newsinfo/316434/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 29 Sep 2026 08:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/316434</guid>
			<atom:subtitle>New research-use products - Adia30M, AdiaClear, and AdiaEXO - give physicians more options in cell count, format, and concentration for investigational studies.</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products</title>
			<link>https://www.newsfilecorp.com/release/315356/Adia-Med-Inc.-Announces-Adia-Labs-Biologic-Inventory-Now-Exceeds-1.5-Million-to-Meet-Rising-Demand-for-the-Companys-Biological-Products</link>
			<description>Winter Park, Florida--(Newsfile Corp. - September 22, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that the estimated retail value of biologic inventory at its laboratory division, Adia Labs LLC, now exceeds $1.5 million, driven by accelerating demand for the Company's biologic products as its ongoing clinical studies expand.Management estimates that Adia Labs'...&lt;img src="https://api.newsfilecorp.com/newsinfo/315356/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 22 Sep 2026 08:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/315356</guid>
		</item>
		<item xml:lang="en">
			<title>Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment</title>
			<link>https://www.newsfilecorp.com/release/314187/Adia-Med-Submits-Fifth-2026-Clinical-Study-to-IRB-Osteoarthritis-Protocol-for-OneTime-Systemic-Treatment</link>
			<description>Winter Park, Florida--(Newsfile Corp. - September 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted a clinical study protocol to an Institutional Review Board for review and approval.The proposed study is designed to evaluate a one-time systemic treatment with AdiaVita, the Company's umbilical cord blood-derived stem cell and exosome product, in adults with osteoarthritis. Participation is...&lt;img src="https://api.newsfilecorp.com/newsinfo/314187/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 15 Sep 2026 08:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/314187</guid>
		</item>
		<item xml:lang="en">
			<title>Nasdaq Shareholder Requirements Just Verified By Adia Med</title>
			<link>https://www.newsfilecorp.com/release/312989/Nasdaq-Shareholder-Requirements-Just-Verified-By-Adia-Med</link>
			<description>Winter Park, Florida--(Newsfile Corp. - September 8, 2026) -  Nasdaq requires companies seeking an initial listing on the Nasdaq Capital Market to have a sufficiently broad public shareholder base. That distribution test includes:At least 300 round-lot holders;A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; andAdia Med has just verified that it currently has 361 round-lot holders, or 61 holders above Nasdaq's 300-holder minimum.Nasdaq Shareholder...&lt;img src="https://api.newsfilecorp.com/newsinfo/312989/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Tue, 08 Sep 2026 08:00:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/312989</guid>
		</item>
	</channel>
</rss>
